Treatment of amyloidogenic diseases
US8784810B2 · kind B2 · utility
16Cited by
194References
2Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 17, 2008 |
| Grant date | Jul 22, 2014 |
| Priority date | — |
| Expiry date | Oct 17, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.